[-] Show simple item record

Need an add-on to metformin? Consider this

URI
https://hdl.handle.net/10355/59116
dc.contributor.authorWyncott, Davideng
dc.contributor.authorLyon, Coreyeng
dc.contributor.authorMounsey, Anneeng
dc.contributor.otherFamily Physicians Inquiries Networkeng
dc.date.issued2017eng
dc.descriptionReview of: Ou SM, Shih CJ, Chao PW, et al. Effects of clinical outcomes of adding dipeptidyl peptidase-4 inhibitors versus sulfonylureas to metformin therapy in patients with type 2 diabetes mellitus. Ann Intern Med. 2015;163:663-672.1.eng
dc.description.abstractNeed an add-on to metformin? Consider this. Sulfonylureas have been the preferred add-on therapy to metformin for T2DM, but a study finds that DPP-4s have lower risks of death, CV events, and hypoglycemia. Practice changer: Consider a dipeptidyl peptidase-4 inhibitor before a sulfonylurea for patients with type 2 diabetes mellitus who require therapy in addition to metformin.eng
dc.identifier.urihttps://hdl.handle.net/10355/59116
dc.languageEnglisheng
dc.publisherFamily Physicians Inquiries Networkeng
dc.relation.ispartofcollectionPriority Updates to Research Literature (PURLs) (2017)eng
dc.relation.ispartofcommunityUniversity of Missouri-Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Networkeng
dc.relation.ispartofseriesJournal of family practice, 66, no. 01 (January 2017): 42-44.eng
dc.rightsOpenAccess.eng
dc.rights.licenseThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.eng
dc.subject.otherSulfonylureaseng
dc.subject.otherMetformineng
dc.subject.otherDipeptidyl peptidase 4 inhibitoreng
dc.subject.otherType 2 diabetes mellituseng
dc.titleNeed an add-on to metformin? Consider thiseng
dc.typeArticleeng


Files in this item

[PDF]
Name:
JFP06601042.pdf
Size:
83.94Kb
Format:
PDF
View/Open

This item appears in the following Collection(s)

[-] Show simple item record